Associated tags: Infection, Escherichia coli, Euronext, Staphylococcus aureus, Fungal infection, Pseudomonas aeruginosa, CAC, Therapy, Pharmaceutical industry, CEST, Patient, S. aureus, Phage therapy
Locations: LYON, FR, NEW YORK, MA, UNITED STATES, PARIS
Attention,
ADS,
Greenwich Street,
Bank,
Depositary,
Sale,
American depositary receipt,
BIC,
Therapy,
Security (finance),
Settlement,
Infection,
BNY Mellon,
DTC Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.
Key Points:
- Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.
- The Bank of New York Mellon serves as depositary (the “Depositary”) for the Company’s ADS facility.
- On or about May 28, 2024, the Depositary may elect to sell the underlying ordinary shares.
- Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.
Retrieved on:
Tuesday, February 20, 2024
Attention,
ADS,
Greenwich Street,
Bank,
Depositary,
Sale,
American depositary receipt,
BIC,
Therapy,
Settlement,
Infection,
BNY Mellon,
Euronext Paris,
DTC,
Security (finance) The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.
Key Points:
- The Company listed the ADSs on The Nasdaq Global Select Market in November 2017 under the ticker ERYP, and subsequently transferred the listing of its ADSs to The Nasdaq Capital Market in April 2023.
- “Given PHAXIAM’s current stage of development, we have determined that delisting from the Nasdaq market was the wisest business and financial decision for the company.
- PHAXIAM Therapeutics remains listed on Euronext Paris as its primary trading market and intends to continue its disclosures in compliance with applicable French financial market regulations.
- Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.
Retrieved on:
Thursday, January 18, 2024
Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024.
Key Points:
- Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024.
- Cash position as of December 31, 2023
With the implementation of additional cost-cutting measures, PHAXIAM Therapeutics estimates that its current cash position will enable the Company to finance its current programs and expected operating expenses until the end of July 2024.
- At the same time, PHAXIAM is continuing discussions aimed at refinancing the company during the first half of 2024, to pursue its project.
- Update on business and key financial data for Q1 2024: press release on May 15, 2024 (after US market close), followed by a conference call and webcast on May 16, 2024 (2:30 pm CET/ 8:30 am ET).
Retrieved on:
Tuesday, November 14, 2023
Webcast,
Research,
POC,
European Medicines Agency,
Lysin,
Therapy,
Infection,
Conference call,
Bank statement,
S. aureus,
Escherichia coli,
S,
Risk,
Mortality,
Phage therapy,
EMA,
ANSM,
Patient,
CET,
AAC,
FDA,
Klebsiella pneumoniae,
Fungal infection,
Health,
Pseudomonas aeruginosa,
Partnership,
CMC,
IVD,
EI,
Cryptocurrency,
Pharmaceutical industry,
Dietary supplement,
Medical device,
Vaccine,
Conference,
Bloodstream infections The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
Key Points:
- The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
- Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
- In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
- Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.
Retrieved on:
Tuesday, October 24, 2023
Fungal infection,
Stroke,
Phage therapy,
Staphylococcus aureus,
Incidence,
National Agency for Food and Drug Administration and Control,
Heart,
Medication,
Teaching hospital,
Hope,
Mortality,
Endocarditis,
Safety,
ANSM,
Infection,
CEST,
Pharmacokinetics,
Endocardium,
Clinical trial,
S. aureus,
Jean-Pierre du Teil,
Bacteria,
Blood,
S,
Therapy,
Patient,
Heart failure,
CPP,
Pharmaceutical industry Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
Key Points:
- Endocarditis is an infection of the endocardium (inner lining of the heart) and valves, usually caused by bacteria.
- The main cause of endocarditis infections, S. aureus, is responsible for around 30%1 of cases.
- Pascal Birman, Chief Medical Officer of PHAXIAM Therapeutics, stated: "This phase 1 study was designed primarily to assess the safety and pharmacokinetics of our anti-S. aureus phages in the treatment of endocarditis infections.
- The treatment of endocarditis infections caused by S. aureus using phage therapy could thus offer a major alternative and hope to many patients who have reached a therapeutic impasse.”
Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares.
Key Points:
- Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares.
- In its initiation study entitled “Ambition de leadership mondial de la phagothérapie - Ambition for global leadership in phage therapy” (only available in French), TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share1.
A retrospective analysis was carried out with 105 clinical Staphylococcus aureus strains which were tested using PHAXIAM’s phagogram in the context of clinical trials, salvage therapy and early access program (AAC).
Key Points:
- A retrospective analysis was carried out with 105 clinical Staphylococcus aureus strains which were tested using PHAXIAM’s phagogram in the context of clinical trials, salvage therapy and early access program (AAC).
- The results demonstrated that 98% of these pathogenic S. aureus strains were susceptible to at least one of the two PHAXIAM’s anti-S. aureus phages (PP1493 and PP1815).
- Phagogram is an in vitro diagnostic (IVD) test designed to determine the in-vitro activity of PHAXIAM’s phages to patients’ bacterial strains.
- The 98% spectrum of activity of our anti-S. aureus phages is exceptionally high when compared with other competing solutions.
Retrieved on:
Wednesday, October 4, 2023
Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2).
Key Points:
- Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2).
- With closing bid price of PHAXIAM’s American Depositary Shares (“ADSs”) above $1.00 per ADS for the 10 consecutive business days from September 18 through September 29, 2023, PHAXIAM has regained compliance with Listing Rule 5550(a)(2).
- On July 27, 2023, PHAXIAM announced a 10-to-1 reverse share split of its shares and ADSs to cure this deficiency, and the reverse share and ADS splits were effected as of September 18, 2023.
- With Nasdaq’s notice that the Company has regained compliance, this matter is now closed.
Heart,
Human,
Partnership,
Infection,
Research,
Animal,
CEST,
Phage therapy,
Knowledge,
Health,
Therapy,
Pharmaceutical industry,
Antibiotics Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy
Key Points:
- Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy
Lyon (France) and Cambridge (MA, US), October 03, 2023 – 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.
- The company enables PHAXIAM Therapeutics to screen its broad phage and endolysin bank targeting highly antimicrobial-resistant infections.
- This agreement gives PHAXIAM Therapeutics exclusive licensing options on specified phages and endolysins in human health from the Vetophage platform, to further strengthen its product portfolio.
- « The agreement with Vetophage is a significant milestone for PHAXIAM Therapeutics' development in the fight against severe resistant infections.
Retrieved on:
Thursday, September 21, 2023
DFU,
Hip,
Infection,
IST,
S. aureus,
Bank statement,
Fungal infection,
Cutis marmorata telangiectatica congenita,
Escherichia coli,
Authorization,
Financial statement,
Staphylococcus,
Trial of the century,
Klebsiella pneumoniae,
Pseudomonas aeruginosa,
Diabetic foot ulcer,
Patient,
VAP,
Risk,
AAC,
AMF,
POC,
Therapy,
System,
Diabetic foot,
ANSM,
Antibiotics,
Pharmaceutical industry,
Vaccine,
Urinary tract infection,
Lysin,
Bloodstream infections The company is awaiting a second AAC regulatory validation for PJI patients, associated with P. aeruginosa resistance from the ANSM.
Key Points:
- The company is awaiting a second AAC regulatory validation for PJI patients, associated with P. aeruginosa resistance from the ANSM.
- On September 19, 2023, the company announced the extension of its portfolio to Klebsiella pneumoniae, a new resistant aggressive bacterial target.
- Key financial figures for the first half of 2023 compared with the same period of the previous year are summarized below.
- In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as of the date of the merger, i.e.
